Oncology

Latest News

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

September 6th 2025

Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com
Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

September 6th 2025

Most of the patients who experienced superior outcomes with atezolizumab and chemotherapy had higher levels of NOTCH1 expression. | Image credit: Pixel-Shot - stock.adobe.com
NOTCH1 Levels Impact Immune Response in SCLC

September 2nd 2025

The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer - stock.adobe
Neoadjuvant Immunotherapy Plus Chemotherapy Shows Promise in LS-SCLC

August 31st 2025

PD-1 blockade has previously shown success in a first-line setting in ES-SCLC, and nab-paclitaxel is albumin-bound and solvent-free, which the investigators explained may minimize the toxicity associated with paclitaxel therapy. | Image credit: didesign - stock.adobe.com
Camrelizumab Plus Carboplatin, Nab-Paclitaxel Shows Efficacy in ES-SCLC

August 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
September 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 7th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Site Logo
February 14th 2019

Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma

Mary Caffrey
Evidence-Based OncologyTM recently sat down with Rodabe Amaria, MD, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine, at MD Anderson and a lead author on a study that found that evidence has been accumulating in preclinical models that neoadjuvant treatment may be superior to treatment after surgery for patients with advanced melanoma.
What We're Reading: Pediatric Mental Health Care; Brain Cancer Immunotherapy; Preventing Perinatal Depression
February 13th 2019

What We're Reading: Pediatric Mental Health Care; Brain Cancer Immunotherapy; Preventing Perinatal Depression

AJMC Staff
Half of children in with treatable mental health disorders in the United States do not get treatment; a small study demonstrated benefit with immunotherapy for glioblastoma; a task force recommends counseling services for new mothers at risk of depression.
Despite Being Involved in Cancer Treatment Decisions, PCPs Lack Knowledge, Confidence
February 13th 2019

Despite Being Involved in Cancer Treatment Decisions, PCPs Lack Knowledge, Confidence

Jaime Rosenberg
While one-third of primary care providers (PCPs) reported participating in breast cancer treatment decisions with their patients, a significant amount of them also indicated that they were not comfortable or did not feel that they had the necessary knowledge to participate in the treatment decision-making process.
Site Logo
February 13th 2019

Is Immunotherapy the Future of Glioblastoma Treatment?

Samantha DiGrande
Immunotherapy has seen great success in the treatment of numerous cancers, from melanoma to lung, breast, colorectal, kidney, and even some brain cancers. But thus far, despite several attempts, the devastating brain disease glioblastoma has not been among the immunotherapy success stories. In fact, glioblastoma researchers have had few advances in more than a decade.
Site Logo
February 12th 2019

Rutgers' Janice Mehnert, MD, on Biomarkers, Being Inclusive in Clinical Trials, and Taking Time to Weigh the Options

Mary Caffrey
From her vantage point at Rutgers Cancer Institute of New Jersey, Janice Mehnert, MD, has had a front-row seat to the immuno-oncology revolution. Mehnert returned to her alma mater in 2007, and since 2014, she has headed Rutgers’ Phase I/ Developmental Therapeutics Program; she is also head of the melanoma research team. Her work on the KEYNOTE-028 trial has produced important results in multiple cancers, including neuroendocrine tumors, thyroid cancer, small cell lung cancer, and, recently, advanced ovarian cancer.
Preparing Patients and the Health System for Curative Therapies in the Pipeline
February 12th 2019

Preparing Patients and the Health System for Curative Therapies in the Pipeline

Laura Joszt, MA
Experts at the “Paying for Cures: Ensuring patient access and system sustainability" event discussed how the healthcare system can pay for curative therapies that have high upfront costs with benefits that accrue over time.
Treatment Advances Averted More Than Half a Million Breast Cancer Deaths Over 3 Decades
February 12th 2019

Treatment Advances Averted More Than Half a Million Breast Cancer Deaths Over 3 Decades

Wallace Stephens
Preventive screening and treatment advances have contributed to saving lives for patients with breast cancer. A new study has identified that these changes could be responsible for averting up to 614,500 breast cancer deaths since 1989.
Identifying Patient Preferences in MM Treatment Improves Shared Decision Making
February 10th 2019

Identifying Patient Preferences in MM Treatment Improves Shared Decision Making

Laura Joszt, MA
Two studies presented at the 60th American Society of Hematology Annual Meeting and Exposition examined patient preferences in multiple myeloma (MM) treatment and the importance of understanding these preferences when making treatment decisions.
Podcast: This Week in Managed Care—State of the Union Health Initiatives and Other Health News
February 10th 2019

Podcast: This Week in Managed Care—State of the Union Health Initiatives and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Careful Observation of Ovarian Cysts Safe Alternative to Surgery
February 9th 2019

Careful Observation of Ovarian Cysts Safe Alternative to Surgery

Samantha DiGrande
Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.
This Week in Managed Care: February 8, 2019
February 8th 2019

This Week in Managed Care: February 8, 2019

This week, the top managed care news included President Trump's State of the Union address highlighting healthcare; HHS Secretary Alex Azar taking on drug rebates; and physicians asking Congress to fully implement the HITECH Act.
Trump Highlights New Initiatives for Childhood Cancer, HIV in State of the Union
February 6th 2019

Trump Highlights New Initiatives for Childhood Cancer, HIV in State of the Union

Laura Joszt, MA
During his second State of the Union address, President Trump highlighted past bipartisan accomplishments, such as legislation to confront the opioid crisis, but also outlined future priorities, such as addressing the cost of healthcare and prescription drugs.
What We're Reading: Obesity and Cancer; Second Patient Treated Under Right-to-Try; Brain Aging
February 6th 2019

What We're Reading: Obesity and Cancer; Second Patient Treated Under Right-to-Try; Brain Aging

AJMC Staff
Cancers related to obesity are on the rise, especially among millennials; a right-to-try advocate is receiving treatment for his amyotrophic lateral sclerosis under the new law; and women's brains age more slowly than men's.
VA Contract Makes Foundation Medicine Oncology Tests Available to Veterans
February 5th 2019

VA Contract Makes Foundation Medicine Oncology Tests Available to Veterans

Laura Joszt, MA
Foundation Medicine announced that it has won a nationwide contract from the Department of Veterans Affairs National Precision Oncology Program. The contract covers all of Foundation Medicine’s tests.
Chronic Pain the Top Reason US Patients Seek Medical Marijuana
February 5th 2019

Chronic Pain the Top Reason US Patients Seek Medical Marijuana

Allison Inserro
Chronic pain accounted for 62.2% of all patient-reported qualifying conditions under which US patients sought medical marijuana, according to a new paper in Health Affairs.
Podcast: This Week in Managed Care—Congressional Drug Price Hearings and Other Health News
February 3rd 2019

Podcast: This Week in Managed Care—Congressional Drug Price Hearings and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Predicting AML Outcomes by Monitoring Minimal Residual Disease
February 2nd 2019

Predicting AML Outcomes by Monitoring Minimal Residual Disease

Laura Joszt, MA
Abstracts presented at the 60th American Society of Hematology Annual Meeting & Exposition looked at how monitoring minimal residual disease can help predict outcomes in acute myeloid leukemia (AML).
Review Identifies Potential Predictive Biomarkers in Colorectal Cancer
February 2nd 2019

Review Identifies Potential Predictive Biomarkers in Colorectal Cancer

David Bai, PharmD
A recent review outlined a vast array of biomarkers that may have clinical implications on the treatment and prognosis of colorectal cancer (CRC).
This Week in Managed Care: February 1, 2019
February 1st 2019

This Week in Managed Care: February 1, 2019

This week, the top managed care news included House and Senate hearings on the cost of prescription drugs; a study finding patients with diabetes can be safely switched to cheaper insulin; and the first non-chemotherapy combination being approved for the treatment of chronic lymphocytic leukemia.
AJMC® in the Press, February 1, 2019
February 1st 2019

AJMC® in the Press, February 1, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
ASCO Names "Progress in Treating Rare Cancers" as the Advance of the Year
January 31st 2019

ASCO Names "Progress in Treating Rare Cancers" as the Advance of the Year

Jaime Rosenberg
Reflecting on a year of breakthrough advancements in the treatment of rare, difficult to treat cancers, the American Society of Clinical Oncology (ASCO) has named “Progress in Treating Rare Cancers” as the Advance of the Year.
Discussing the Continuing Decline in Overall Cancer Mortality in the United States
January 30th 2019

Discussing the Continuing Decline in Overall Cancer Mortality in the United States

In this podcast, we speak with Rebecca Siegel, MPH, strategic director of surveillance information services in the Intramural Research Department at the American Cancer Society, and the lead author of the annual Cancer Statistics report that estimates the number of new cancer cases and deaths in the United States each year.
Site Logo
January 30th 2019

Mantle Cell Lymphoma (MCL): Treatment Landscape and Access to Care

https://www.pharmacytimes.org/on-demand/mantle-cell-lymphoma-mcl-treatment-landscape-and-access-to-care
Care Coordination Is the Top Investment Cancer Programs Can Make, Respondents Say
January 29th 2019

Care Coordination Is the Top Investment Cancer Programs Can Make, Respondents Say

Laura Joszt, MA
The ninth annual Trending Now in Cancer Care survey identified current and emerging trends for US cancer programs, such as the ongoing threat of drug costs and popular services progams are planning to add in the next 2 years.
FDA Approves Ibrutinib Combination as Frontline Treatment for CLL
January 29th 2019

FDA Approves Ibrutinib Combination as Frontline Treatment for CLL

Jaime Rosenberg
The approval marks the first non-chemotherapy combination regimen for the treatment of patients with chronic lymphocytic leukemia (CLL).
Site Logo
January 23rd 2019

Managed Care Considerations in Meeting the Complex Needs of Patients with Pancreatic Cancer

https://www.pharmacytimes.org/on-demand/managed-care-considerations-in-meeting-the-complex-needs-of-patients-with-pancreatic-cancer
Treatment Advances Make Supportive Care More Important in Multiple Myeloma
January 22nd 2019

Treatment Advances Make Supportive Care More Important in Multiple Myeloma

Laura Joszt, MA
As patients with multiple myeloma live longer thanks to advancements in treatments, more attention is being paid to treatment-related toxicities that are becoming more relevant.
Podcast: This Week in Managed Care—New Drug Pricing Probe and Other Health News
January 20th 2019

Podcast: This Week in Managed Care—New Drug Pricing Probe and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Dr Sibel Blau Discusses the Role of the Quality Cancer Care Alliance
January 20th 2019

Dr Sibel Blau Discusses the Role of the Quality Cancer Care Alliance

As the first clinically integrated oncology network, the Quality Cancer Care Alliance (QCCA) brings together the best practices and shares knowledge on value-based care, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy
January 19th 2019

Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy

Jaime Rosenberg
Higher tumor mutational burden is associated with improved overall survival in patients with stage IV or metastatic disease being treated with immune checkpoint inhibitors.
<1
...
333435363738394041
...
188>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo